METHODS OF USING SOLID DISPERSIONS OF RIFAXIMIN FOR THE TREATMENT OF SICKLE CELL DISEASE
Provided herein are solid dispersions comprising rifaximin and methods of using the same for the treatment of sickle cell disease (SCD).
1 . A method of treating sickle cell disease (SCD) in a patient in need thereof comprising administering at least one rifaximin SSD composition to the patient.
2 . A method of reducing elevated levels of circulating aged neutrophils (CANs) in a patient in need thereof comprising administering at least one rifaximin SSD composition to the patient.
3 . A method of treating vaso-occlusive crises (VOCs) in a patient in need thereof comprising administering at least one rifaximin SSD composition to the patient.
4 . The method according to claim 1 , wherein the at least one rifaximin SSD composition comprises an immediate release (IR) tablet, a sustained extended release (SER) tablet, or a combination thereof.
5 . The method according to claim 1 , wherein the at least one rifaximin SSD composition comprises at least one 40 mg rifaximin SSD IR tablet, an 80 mg rifaximin SSD IR tablet, a 40 mg SSD SER tablet, an 80 mg SSD SER tablet, or a combination thereof.
6 . The method according to claim 1 , wherein the at least one rifaximin SSD composition comprises at least one rifaximin SSD IR tablet.
7 . The method according to claim 6 , wherein the at least one rifaximin SSD IR tablet comprises a 40 mg rifaximin SSD IR tablet, an 80 mg rifaximin SSD IR tablet, or a combination thereof.
8 . The method according to claim 1 , wherein administering the at least one rifaximin SSD composition to the patient comprises delivering the at least one rifaximin SSD composition QD, BID, TID, or QID to the patient.
9 . The method of claim 8 , wherein administering the at least one rifaximin SSD composition to the patient comprises delivering the at least one rifaximin SSD composition QD or BID to the patient.
10 . The method of claim 9 , wherein administering the at least one rifaximin SSD composition to the patient comprises delivering the at least one rifaximin SSD composition BID to the patient.
11 . The method according to claim 1 , wherein administering the at least one rifaximin SSD composition to the patient comprises delivering the at least one rifaximin SSD composition to the patient for a period of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months.
12 . (canceled)
13 . (canceled)
14 . The method according to claim 1 , wherein the at least one rifaximin SSD composition comprises at least two, three, or four rifaximin SSD tablets.
15 . (canceled)
16 . The method of claim 14 , wherein the at least one rifaximin SSD composition comprises at least one, two, three, or four 40 mg rifaximin SSD IR tablets.
17 . (canceled)
18 . The method of claim 14 , wherein the at least one rifaximin SSD composition comprises at least one or two 80 mg rifaximin SSD IR tablets.
19 . The method according to claim 1 , further comprising administering an additional SCD therapeutic agent to the patient.
20 . The method of claim 19 , wherein the additional SCD therapeutic agent comprises hydroxyurea, L-glutamine, hydroxycarbamide, an erythropoietin stimulating agent, an opioid analgesic, or a combination thereof.
21 . (canceled)
22 . The method according to claim 3 , wherein the method of treating vaso-occlusive crises (VOCs) in the patient in need thereof comprises alleviating one or more symptoms of VOCs in the patient.
23 . The method according to claim 3 , wherein the method of treating vaso-occlusive crises (VOCs) in the patient in need thereof comprises reducing or preventing the occurrence of VOCs in the patient.
24 . The method according to claim 3 , wherein the method of treating vaso-occlusive crises (VOCs) in the patient in need thereof comprises reducing the duration or severity of VOCs in the patient.
25 . The method according to claim 3 , wherein the method of treating vaso-occlusive crises (VOCs) in the patient in need thereof comprises mediating or otherwise reducing the patient's opioid usage during VOCs.